MNDL Bio
Herzliya · Founded 2023
About MNDL Bio
MNDL Bio is revolutionizing the field of synthetic biology with its AI-powered gene expression optimization platform. By leveraging advanced computational models and machine learning algorithms developed over 15 years of research, MNDL Bio provides an unprecedented ability to rapidly recode target genes for maximum gene expression in host organisms. This disruptive technology streamlines workflows, accelerates timelines, boosts yields, and dramatically reduces costs compared to traditional trial-and-error methods. MNDL Bio is helping biotech companies, pharmaceutical innovators, and foodtech researchers unleash the full potential of engineered biology. Led by world-renowned experts in synthetic biology and gene expression, MNDL Bio combines cutting-edge science with proprietary technologies to drive the bio-revolution and shape the future of synthetic biology as a transformative force.
Company Facts
- Founded: 2023
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $2.0M
- Funding stage: Seed
- Last round: Non-Equity Assistance (Apr 2025)
- Website: https://mndl.bio/
- Phone: info@mndl.bio
Industries & Categories
Biotechnology, Genetics, Software
Social Profiles
Canonical: https://fsome.com/organization/mndl-bio-844 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.